Peptide knowledge, connected to its evidence.

At a glance

What is it—and why does it matter?

Tirzepatide is described as an incretin-based agent that agonizes both GIP and GLP-1 receptors. As a dual GIP/GLP-1 receptor agonist, tirzepatide is stated to increase biphasic insulin secretion and decrease glucagon, with both actions described as glucose-dependent. The source states a comparative improvement in glycaemic control and body weight with tirzepatide versus dulaglutide 0.75 mg, semaglutide 1 mg, and insulin in inadequately controlled T2DM, with use either as monotherapy or combination therapy. The contraindications list includes a history of serious hypersensitivity to tirzepatide or excipients as a reason not to use MOUNJARO.

Evidence behind this overview

[1][2][3][4]

Each sentence above is copied from a published claim presentation. The links open its evidence record.

ClassDual GIP/GLP-1 receptor agonist

Structure39 amino acids

StatusFDA-approved ingredient

Products in this profile2

The important boundary

Mounjaro and Zepbound share an ingredient but not a single indication or dosing record. [1]

Identity + structure

A molecule, not a product name.

Chemical identity and product identity are kept separate so evidence does not leak between formulations or indications.

Preferred name	Tirzepatide	Ingredient
Pharmacologic class	Dual GIP/GLP-1 receptor agonist	Profile record
Peptide structure	39 amino acids	Profile record
Also indexed as	tirzepatide · dual incretin agonist	Search aliases

Mechanism + clinical pharmacology

Target, response, and disposition.

Primary explanation

Agonism at GIP and GLP-1 receptors increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and reduces food intake. [1]

Evidence ledger

What the evidence says.

250 profile findings. Contextual and unclassified research is listed separately below. Open each citation to inspect the source and its limitations.

These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.

Study findings

What studies observed in defined populations, comparators, and time periods.

86 statements

Source-backed statement

The study reported a lower hazard of acute myocardial infarction associated with tirzepatide versus GLP-1 receptor agonists, expressed as an HR with 95% CI.

Sources[49]

Source-backed statement

In obesity/overweight with prediabetes, long-term tirzepatide treatment was associated with a lower Framingham-predicted 10-year CVD risk compared with placebo.

Sources[65]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In this retrospective cohort of adults starting tirzepatide for obesity, the mean percent weight loss at 12 months among those with recorded weights was -17.4%, with a 95% confidence interval of -17.5 to -17.3.

Sources[63]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In this retrospective cohort comparison, tirzepatide initiation was associated with improved glycaemic control versus matched controls, measured by a mean HbA1c reduction with a reported confidence interval and p-value.

Sources[36]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Tirzepatide treatment decreased food intake in both male and female mice (direction: reduction).

Sources[94]

Source-backed statement

Using a one-year time horizon, persistence on tirzepatide (Zepbound) was 81.9% in this cohort.

Sources[41]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Using retrospective cohort data with propensity score matching, TZP initiation was associated with a lower hazard of acute asthma exacerbation versus sulfonylureas.

Sources[91]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Baseline insurance status indicates most participants initiating tirzepatide reported employer-provided health insurance (80.9%).

Sources[56]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The combination arm showed a higher total pregnancy rate than metformin monotherapy, with p = 0.014 reported.

Sources[24]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

An organism-based male db/db mouse study evaluated blood glucose levels 72 hrs after each SC dose (30 nmol/kg every 3 days for 31 days), but did not report an activity result.

Sources[5]

Sources[94]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

An organism-based study in male ICR mice assessed body weight over 4 days after SC dosing at 30 nmol/kg, but did not report an activity result.

Sources[5]

Sources[56]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In a retrospective real-world cohort of youth initiating tirzepatide, BMI decreased from baseline to the first follow-up visit.

Sources[67]

Human research · design must be checked

1 cited source · Study independence not established

Sources[78]

Human research · design must be checked

1 cited source · Study independence not established

Sources[80]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

A cell-based cAMP assay in CHO cells expressing human GLP-1R measured agonism for CHEMBL4297839, with potency EC50 = 0.77 nM after 30 mins incubation.

Sources[5]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Selection criteria are listed, but the magnitude of each effect is not provided in the abstract.

Sources[55]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The data source is a real-world observational longitudinal survey (PERCEPTIONS) with baseline reporting in a US cohort initiating tirzepatide.

Sources[56]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Tirzepatide acts as a dual incretin receptor agonist (GIP and GLP-1) with long-acting activity.

Sources[38]

Human research · design must be checked

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

In CHO cells, CHEMBL4297839 activated the human GLP-1 receptor with an EC50 of 0.77 nM (cAMP assay, 30 minutes).

Sources[5]

Sources[30]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Outcome assessments included CAVI for vascular function and InBody720-derived SMI and BFI for body composition.

Sources[35]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The study operationalized liver disease progression via a composite endpoint (MALO) and analyzed matched cohorts of new users in a TriNetX-based target-trial emulation.

Sources[73]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

This objective frames a real-world, patient-reported assessment in employed adults initiating tirzepatide, focusing on workplace-related outcomes and perceived employer insurance coverage for obesity medications.

Sources[56]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In humans, reductions in appetite and energy intake are supported as major mechanistic contributors to tirzepatide-associated weight reduction.

Sources[80]

To reduce confounding, the analysis used 1:1 propensity score matching incorporating demographics, comorbidities, and IBD medication use.

Sources[93]

Human research · design must be checked

1 cited source · Study independence not established

Sources[14]

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Safety findings

Observed or labeled risks, adverse effects, and safety signals.

6 statements

Source-backed statement

This statement is based on rodent findings at clinically relevant exposures; it does not by itself establish the same risk in humans.

Sources[9]

Animal / laboratory evidence

1 cited source · 1 regulatory record

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

This warning describes an observed risk and provides a management recommendation; it does not quantify incidence in this section.

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

Sources[13]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Regulatory status

Product-, indication-, and jurisdiction-specific regulatory records.

1 statement

Source-backed statement

The labeled cardiovascular indication is risk reduction for a composite of CV death, non-fatal MI, or non-fatal stroke in adults with type 2 diabetes at high risk.

Sources[12]

Regulatory record

1 cited source · 1 regulatory record

Sources[10]

Regulatory record

1 cited source · 1 regulatory record

Sources[11]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Studied populations

Who was represented in a study, label, or registry record.

2 statements

Source-backed statement

Across renal impairment severity (including ESRD), tirzepatide pharmacokinetics were unchanged in studied subjects; labeling therefore recommends no dosage adjustment.

Sources[8]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

Mounjaro is used with diet and physical activity for type 2 diabetes in people aged 10 years and above when diabetes is not well controlled.

Sources[16]

Regulatory record

1 cited source · 1 regulatory record

Sources[71]

Sources[93]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Tirzepatide (in MOUNJARO) is characterized as a dual incretin agonist targeting GIP and GLP-1 receptors, intended for once-weekly use.

Sources[10]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Additional research & classification gaps

41 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.

Inspect contextual research (41)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The investigators evaluated consistency between risk-equation–derived hazard ratios and hazard ratios from observed cardiovascular events using REWIND trial data.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
The use of the FHS equation to predict treatment effect (model-derived hazard ratio, HR) was examined for consistency with the observed cardiovascular events in the REWIND trial.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Using P-score rankings from the network meta-analysis, tirzepatide at 15 mg was top-ranked for reductions in weight and waist circumference.

Research context only—not evidence of a treatment effect.

Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
Tirzepatide 15 mg ranked highest for weight and waist reduction across analyses based on P-scores.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Differences in trial design and enrolled populations between SUMMIT and EMPEROR-Preserved mean cross-trial comparisons of tirzepatide versus empagliflozin are not statistically valid.

Research context only—not evidence of a treatment effect.

pubmed-42533465
Because SUMMIT and EMPEROR-Preserved differed in design and populations, direct comparison between agents is not statistically valid; each should be assessed on its own evidence base.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Across June 2024–March 2025 (complete monthly data), monthly dispensing quantity increased from 392,354 to 1,027,955 kit units.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Complete monthly data were available from June 2024 through March 2025. During this interval, monthly quantity increased from 392,354 to 1,027,955 kit units;

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Work productivity and activity impairment (WPAI) at baseline indicated substantial impairment, with reported mean activity and overall work impairment percentages, with presenteeism identified as the primary driver.

Research context only—not evidence of a treatment effect.

pubmed-42518363
WPAI results indicated substantial impairment, with mean activity impairment of 43.0% and overall work impairment of 32.4%, driven primarily by presenteeism.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The primary outpatient total was 7,829,974.7 kit units.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The primary outpatient total was 7,829,974.7 kit units.

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Across the analyzed time course, the results state there were no consistent tirzepatide-associated changes in fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
No consistent associations were observed between tirzepatide and changes in fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.

Over June 2024–March 2025, claims-recorded outside-medical-institution outpatient quantity increased from 329,431 kit units (84.0%) to 899,994 kit units (87.6%).

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
outside-institution quantity increased from 329,431 kit units (84.0%) to 899,994 kit units (87.6%);
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
outside-institution quantity increased from 329,431 kit units (84.0%) to 899,994 kit units (87.6%);

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

The results report adiponectin geometric means increased versus placebo across tirzepatide 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
adiponectin (21.1%, 35.1%, 47.7%)

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

The results list decreases in the endothelial dysfunction biomarker E-selectin versus placebo across all three tirzepatide doses.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
E-selectin (-12.6%, -20.0%, -26.4%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Automated sentiment analysis of Mounjaro-related tweets found a majority of posts expressed favorable sentiment (62.6%).

Research context only—not evidence of a treatment effect.

Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
Overall sentiment toward Mounjaro was largely positive, with 62.6% of tweets expressing favorable attitudes.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Monthly data were complete from June 2024 through March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Complete monthly data were available from June 2024 through March 2025.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

A post hoc analysis assessed durability of tirzepatide for primary cardiovascular disease prevention in obesity using predicted CVD risk as the basis.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
This post hoc analysis assessed the durability of tirzepatide for primary cardiovascular disease (CVD) prevention in obesity, based on predicted CVD risk, in the SURMOUNT-1 (SM-1) 3-year study.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Beyond the primary signals, the review notes context-dependent concerns involving thiamine, folate, vitamin A, other fat-soluble vitamins, and potassium.

Research context only—not evidence of a treatment effect.

pubmed-42382663
with additional context-dependent concerns involving thiamine, folate, vitamin A, other fat-soluble vitamins and potassium.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The optimized process produced tablets with friability 0.58% and Carr’s index 24.

Research context only—not evidence of a treatment effect.

Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.
yielded tablets with low friability (0.58%) and acceptable flowability (Carr's index, 24).

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Compared with placebo at week 72, tirzepatide was associated with dose-graded reductions in hs-CRP across 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
high-sensitivity C-reactive protein (-36.9%, -46.9%, -54.6%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

52.3% said they would consider switching jobs to get obesity-medicine coverage.

Research context only—not evidence of a treatment effect.

pubmed-42518363
52.3% reported that they would consider changing jobs in order to receive OM coverage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

These figures attribute portions of the observed increase to specific strength categories in claims data.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The 5-mg product accounted for 320,965 kit units (50.5%) of the absolute increase, whereas strengths of 7.5 mg or higher collectively accounted for 195,414 kit units (30.7%).

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

The study collected plasma at three timepoints (baseline, week 24, week 72) for biomarker assays.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
collected at baseline, 24 weeks, and 72 weeks

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In the PERCEPTIONS baseline survey of 518 employees starting tirzepatide, most respondents (81.7%) reported that having obesity medication coverage may increase job satisfaction.

Research context only—not evidence of a treatment effect.

pubmed-42518363
81.7% reported that OM coverage may increase job satisfaction

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The observational dataset comprised 5,566 Mounjaro-related tweets from 5,641 unique accounts collected over January 9–February 24, 2025.

Research context only—not evidence of a treatment effect.

Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
The dataset included 5,566 tweets generated by 5,641 unique users collected between January 9 and February 24, 2025.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In the multivariable model, tirzepatide dose level showed an independent association with weight-loss magnitude, with higher dosage associated with greater weight loss.

Research context only—not evidence of a treatment effect.

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

This network meta-analysis reports a moderate-to-high certainty of evidence rating for tirzepatide (as categorized by the authors).

Research context only—not evidence of a treatment effect.

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
The certainty of evidence was moderate-to-high for GLP1RA, SGLT2i, Tirzepatide, DPP4i; low for metformin; low-to-moderate for other drugs.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In a baseline survey of 518 full-time employees starting tirzepatide, 52.3% reported willingness to consider job changes to obtain employer-provided obesity medication coverage.

Research context only—not evidence of a treatment effect.

pubmed-42518363
52.3% reported that they would consider changing jobs in order to receive OM coverage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The study defined TBWL% at 15 months as the primary endpoint and planned stratified analyses by sex and prespecified age categories, which frames how tirzepatide-associated weight-loss outcomes were evaluated.

Research context only—not evidence of a treatment effect.

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46-59, ≥ 60 years).

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The review highlights key micronutrient-related signals spanning hematologic, fat-soluble, bone-related, trace element, and electrolyte domains, emphasizing iron, vitamin B12, vitamin D, calcium, magnesium, and zinc.

Research context only—not evidence of a treatment effect.

pubmed-42382663
The most relevant signals involve hematologic, fat-soluble, bone-related, trace element, and electrolyte domains, particularly iron, vitamin B12, vitamin D, calcium, magnesium, zinc,

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

A mixed model for repeated measures evaluated change in log-transformed biomarkers, with week 72 change prespecified as the primary outcome of interest.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
with change at 72 weeks the primary outcome of interest

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Monthly quantity rose from 392,354 to 1,027,955 kit units from June 2024 to March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
During this interval, monthly quantity increased from 392,354 to 1,027,955 kit units;

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In a baseline survey of 518 full-time employees starting tirzepatide, nearly all respondents (96.5%) endorsed that employer-provided insurance should cover obesity medications.

Research context only—not evidence of a treatment effect.

pubmed-42518363
Majority (96.5%) believed employer-provided insurance should include OM coverage, citing improved health, productivity, and management of obesity-related complications.

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Compared with placebo at week 72, tirzepatide was associated with reductions in interleukin-6 across the 5, 10, and 15 mg doses.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
interleukin-6 (-25.4%, -27.8%, -30.2%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The 2.5 mg product increased in kit units (159,318 to 278,540) but its share fell (40.6% to 27.1%) from June 2024 to March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The quantity of the 2.5-mg product increased from 159,318 kit units (40.6%) to 278,540 kit units (27.1%), while its share decreased.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The conclusion calls for prospective research to establish incidence, clinical relevance, and evidence-based monitoring strategies related to micronutrient risk during incretin-based obesity pharmacotherapy.

Research context only—not evidence of a treatment effect.

pubmed-42382663
while prospective studies are needed to define incidence, clinical relevance, and evidence-based monitoring strategies.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Mounjaro is the brand name for the drug tirzepatide.

Research context only—not evidence of a treatment effect.

Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
Mounjaro (tirzepatide)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The product name in Japan is Mounjaro, and it is available in six dosage strengths.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
marketed under the brand name Mounjaro, which is available in six strengths.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The study design is described as a secondary analysis of cross-sectional survey data with two data-collection windows.

Research context only—not evidence of a treatment effect.

pubmed-42491427
This secondary analysis utilized data from a cross-sectional survey of physicians and PwO from October 2023 to April 2024, and from October 2024 to January 2025.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Disproportionality metrics (ROR and PRR) were computed by comparing semaglutide to tirzepatide and vice versa, i.e., each drug served as the comparator for the other.

Research context only—not evidence of a treatment effect.

Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
Disproportionality was evaluated using reporting odds ratios (RORs) and proportional reporting ratios (PRRs), utilizing each drug as the other's comparator.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Predicted 10-year cardiovascular disease risk was computed with the Framingham Heart Study (FHS) risk equation.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Predicted 10-year CVD risk was calculated using the Framingham Heart Study (FHS) equation.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The analysis approach was pharmacovigilance disproportionality assessment of cardiovascular adverse-event signals in FAERS, comparing semaglutide with tirzepatide over January 2022–March 2026.

Research context only—not evidence of a treatment effect.

Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
This study aimed to conduct a pharmacovigilance disproportionality analysis comparing cardiovascular adverse event (AE) signals between semaglutide and tirzepatide utilizing Food and Drug Administration Adverse Event Reporting System (FAERS) data from January 2022 to March 2026.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Four standard pharmacovigilance disproportionality algorithms (ROR, PRR, IC, EBGM) were applied to detect reporting signals.

Research context only—not evidence of a treatment effect.

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Disproportionality analysis used four algorithms (ROR, PRR, IC, EBGM).

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The review notes that incretin-therapy mechanisms may alter dietary intake and gastrointestinal physiology and influence metabolic adaptations to weight loss, which is framed as a reason to be concerned about micronutrient disturbances during long-term treatment.

Research context only—not evidence of a treatment effect.

pubmed-42382663
These mechanisms may also modify dietary intake, gastrointestinal physiology, and weight-loss-related metabolic adaptations, raising concern about micronutrient disturbances during long-term treatment.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In reports with valid onset data, the median adverse-event time-to-onset was 13 days; 67.1% occurred within 30 days.

Research context only—not evidence of a treatment effect.

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Among reports with valid onset data, median time to onset was 13 days, with 67.1% occurring within 30 days.

Safety + tolerability

Risks, organized for scanning.

A structured orientation to the label—not a complete prescribing-information substitute or an individual risk estimate.

Boxed warning

Labels warn about thyroid C-cell tumors observed in rats; human relevance is unknown. [1]

Contraindications

Personal or family history of medullary thyroid carcinoma
MEN 2
Serious hypersensitivity to tirzepatide

Common effects

Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Dyspepsia
Abdominal pain

Serious risks

Acute pancreatitis
Hypoglycemia with insulin or secretagogues
Acute kidney injury from dehydration
Gallbladder disease
Severe gastrointestinal reactions

Structured from current product labeling [1]

Products + regulatory context

Same ingredient. Different records.

Brand names, routes, presentations, indications, and instructions are product-specific. This table is an index—not a substitution guide.

Product	Form	Profile scope	Record
Mounjaro	Weekly subcutaneous injection	Type 2 diabetes.	[1]
Zepbound	Weekly subcutaneous injection	Chronic weight management and product-specific obstructive sleep apnea use.	[7]

Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.

Administration, interactions + monitoring

The practical clinical context.

Administration boundary: Once-weekly subcutaneous product with label-directed escalation intended to improve tolerability. [1]

Research status + gaps

What still needs better answers.

A useful knowledge base names uncertainty as clearly as it names findings.

4615 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (2451), assurance_score_below_0.72 (1946), current_regulatory_source_required (823), evidence_scope (672), extraction_ambiguity (1985), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (2115), no_direct_support (4393), proposal_not_staged (66)

How Peplexicon reads evidence

Authority: What kind of source is making the statement?
Independence: Do multiple citations represent separate studies—or the same evidence repeated?
Directness: Does the population, product, dose, outcome, and time horizon match the claim?
Consistency: Do credible sources support, qualify, or contradict one another?

References + discovery

Open the records yourself.

Authoritative records and published evidence are listed separately from live searches, which are discovery tools rather than pre-screened support.

Filter references

1
Regulatory labelMounjaro prescribing information
Current DailyMed label for tirzepatide marketed as Mounjaro.
Open ↗
2
Literature indexEvery PubMed result for tirzepatide
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
Open ↗
3
Trial registryEvery registered study for tirzepatide
Live ClinicalTrials.gov search, including completed, active, and historical records.
Open ↗
4
Chemical recordtirzepatide chemical record
PubChem compound search from the National Library of Medicine.
Open ↗
5
Published evidence snapshotChEMBL activities for CHEMBL4297839
chembl-activities · T6
Published 2026-08-20 · retrieved 2026-08-20T08:28:52Z
Open ↗
6
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-20T08:28:52Z
Open ↗
7
Published evidence snapshotThese highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval:2022
dailymed · T1
Published 2026-08-28 · retrieved 2026-09-06T08:31:50Z
Open ↗
8
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-20T08:28:52Z
Open ↗
9
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-20T08:28:52Z
Open ↗
10
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-21T08:29:16Z
Open ↗
11
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-21T08:29:16Z
Open ↗
12
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-08-27 · retrieved 2026-09-06T08:31:50Z
Open ↗
13
Published evidence snapshotThese highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
dailymed · T1
Published 2026-07-29 · retrieved 2026-08-21T08:29:16Z
Open ↗
14
Published evidence snapshotPopulation pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
doi · T6
Published 2024-02-14 · retrieved 2026-09-08T10:55:59Z
Open ↗
15
Published evidence snapshotTirzepatide Once Weekly for the Treatment of Obesity.
doi · T2
Published 2022-06-04 · retrieved 2026-08-24T17:39:43Z
Open ↗
16
Published evidence snapshotMounjaro | European Medicines Agency (EMA)
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:02:56Z
Open ↗
17
Published evidence snapshotTirzepatide: A Review in Type 2 Diabetes.
pubmed · T3
Published 2024-02-01 · retrieved 2026-09-09T23:09:21Z
Open ↗
18
Published evidence snapshotThe efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.
pubmed · T2
Published 2026-06-01 · retrieved 2026-09-09T23:09:23Z
Open ↗
19
Published evidence snapshotTirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
pubmed · T2
Published 2026-01-01 · retrieved 2026-08-21T08:36:12Z
Open ↗
20
Published evidence snapshotpubmed-42155673
pubmed · T3
Published 2026-08-18 · retrieved 2026-08-18T08:28:36Z
Open ↗
21
Published evidence snapshotpubmed-42168641
pubmed · T3
Published 2026-08-18 · retrieved 2026-08-18T08:28:36Z
Open ↗
22
Published evidence snapshotReal-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-26T08:30:34Z
Open ↗
23
Published evidence snapshotComprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
pubmed · T2
Published 2026-08-11 · retrieved 2026-09-10T08:34:32Z
Open ↗
24
Published evidence snapshotShort-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
pubmed · T2
Published 2026-08-01 · retrieved 2026-09-09T08:33:27Z
Open ↗
25
Published evidence snapshotpubmed-42275945
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z
Open ↗
26
Published evidence snapshotSex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:30:31Z
Open ↗
27
Published evidence snapshotTirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
pubmed · T2
Published 2026-07-10 · retrieved 2026-08-24T08:31:35Z
Open ↗
28
Published evidence snapshotComparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
pubmed · T2
Published 2026-09-01 · retrieved 2026-09-09T08:33:27Z
Open ↗
29
Published evidence snapshot1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-20T08:28:52Z
Open ↗
30
Published evidence snapshotTirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE-/-mice.
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-20T08:28:52Z
Open ↗
31
Published evidence snapshotpubmed-42362122
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z
Open ↗
32
Published evidence snapshotpubmed-42382663
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:03:18Z
Open ↗
33
Published evidence snapshotReal-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
pubmed · T3
Published 2026-06-30 · retrieved 2026-08-26T08:30:34Z
Open ↗
34
Published evidence snapshotTirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-02T08:35:46Z
Open ↗
35
Published evidence snapshotImpact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-05T08:30:31Z
Open ↗
36
Published evidence snapshotReal-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-09T08:33:27Z
Open ↗
37
Published evidence snapshotChanges in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.
pubmed · T3
Published 2026-07-07 · retrieved 2026-08-24T08:31:35Z
Open ↗
38
Published evidence snapshotEffects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.
pubmed · T3
Published 2026-07-07 · retrieved 2026-08-24T08:31:35Z
Open ↗
39
Published evidence snapshotNeuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-09T08:33:27Z
Open ↗
40
Published evidence snapshotComparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-25T08:29:46Z
Open ↗
41
Published evidence snapshotPatterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
pubmed · T3
Published 2026-07-09 · retrieved 2026-08-24T08:31:35Z
Open ↗
42
Published evidence snapshotInfluence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
pubmed · T3
Published 2026-07-10 · retrieved 2026-09-11T08:35:08Z
Open ↗
43
Published evidence snapshotLower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.
pubmed · T3
Published 2026-07-11 · retrieved 2026-08-24T08:31:35Z
Open ↗
44
Published evidence snapshotpubmed-42436850
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:02:04Z
Open ↗
45
Published evidence snapshotSafety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
46
Published evidence snapshotIncident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.
pubmed · T3
Published 2026-07-14 · retrieved 2026-08-23T08:27:39Z
Open ↗
47
Published evidence snapshotTirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-25T08:29:46Z
Open ↗
48
Published evidence snapshotEffect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
pubmed · T3
Published 2026-07-16 · retrieved 2026-08-23T08:27:39Z
Open ↗
49
Published evidence snapshotComparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
pubmed · T3
Published 2026-07-21 · retrieved 2026-09-06T08:31:50Z
Open ↗
50
Published evidence snapshotMulti-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-19T08:29:05Z
Open ↗
51
Published evidence snapshotComparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
pubmed · T2
Published 2026-07-01 · retrieved 2026-08-25T08:29:46Z
Open ↗
52
Published evidence snapshotPersonalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-19T08:29:05Z
Open ↗
53
Published evidence snapshotpubmed-42491427
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z
Open ↗
54
Published evidence snapshotA Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-22T08:27:44Z
Open ↗
55
Published evidence snapshotOvercoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.
pubmed · T3
Published 2026-07-05 · retrieved 2026-08-25T08:29:46Z
Open ↗
56
Published evidence snapshotpubmed-42518363
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z
Open ↗
57
Published evidence snapshotReal-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-23T08:27:39Z
Open ↗
58
Published evidence snapshotLow-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
59
Published evidence snapshotEffect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
pubmed · T2
Published 2026-10-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
60
Published evidence snapshotpubmed-42533465
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:05:51Z
Open ↗
61
Published evidence snapshotOutpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-21T08:29:16Z
Open ↗
62
Published evidence snapshotTirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.
pubmed · T3
Published 2026-08-05 · retrieved 2026-08-25T08:29:46Z
Open ↗
63
Published evidence snapshotReal-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
64
Published evidence snapshotAnalysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
pubmed · T3
Published 2026-08-06 · retrieved 2026-08-18T20:56:12Z
Open ↗
65
Published evidence snapshotPredicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
pubmed · T3
Published 2026-08-10 · retrieved 2026-08-18T08:28:36Z
Open ↗
66
Published evidence snapshotpubmed-42572932
pubmed · T3
Published 2026-08-18 · retrieved 2026-08-18T08:28:36Z
Open ↗
67
Published evidence snapshotReal-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.
pubmed · T3
Published 2026-08-12 · retrieved 2026-09-05T08:30:31Z
Open ↗
68
Published evidence snapshotAnti-Obesity Medications in Longevity and Aesthetic Medicine.
pubmed · T3
Published 2026-08-03 · retrieved 2026-08-18T20:56:12Z
Open ↗
69
Published evidence snapshotIncretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-18T20:56:12Z
Open ↗
70
Published evidence snapshotpubmed-42597512
pubmed · T3
Published 2026-08-18 · retrieved 2026-08-18T08:28:36Z
Open ↗
71
Published evidence snapshotThe Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.
pubmed · T3
Published 2026-08-01 · retrieved 2026-09-05T08:30:31Z
Open ↗
72
Published evidence snapshotProspective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
pubmed · T3
Published 2026-08-18 · retrieved 2026-08-19T08:29:05Z
Open ↗
73
Published evidence snapshotMajor Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.
pubmed · T3
Published 2026-08-19 · retrieved 2026-08-21T08:29:16Z
Open ↗
74
Published evidence snapshotTrends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-08T16:35:00Z
Open ↗
75
Published evidence snapshotTrends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.
pubmed · T3
Published 2026-08-24 · retrieved 2026-08-26T08:30:34Z
Open ↗
76
Published evidence snapshotComparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-27T11:42:45Z
Open ↗
77
Published evidence snapshotClinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
78
Published evidence snapshotComparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
pubmed · T2
Published 2026-10-01 · retrieved 2026-09-11T08:35:08Z
Open ↗
79
Published evidence snapshotAssociation of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
pubmed · T2
Published 2026-08-31 · retrieved 2026-09-09T08:33:27Z
Open ↗
80
Published evidence snapshotTirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:30:31Z
Open ↗
81
Published evidence snapshotBrca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism.
pubmed · T3
Published 2026-09-02 · retrieved 2026-09-11T08:35:08Z
Open ↗
82
Published evidence snapshotPostmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:30:31Z
Open ↗
83
Published evidence snapshotComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:30:31Z
Open ↗
84
Published evidence snapshotFrom insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:30:31Z
Open ↗
85
Published evidence snapshotGlucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
pubmed · T3
Published 2026-09-03 · retrieved 2026-09-05T08:30:31Z
Open ↗
86
Published evidence snapshotSuspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.
pubmed · T3
Published 2026-08-01 · retrieved 2026-09-06T08:31:50Z
Open ↗
87
Published evidence snapshotTirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-06T08:31:50Z
Open ↗
88
Published evidence snapshotTirzepatide-Based Therapy for Multidomain Metabolic Improvement in an Active Duty Service Member: A Case Report.
pubmed · T3
Published 2026-08-01 · retrieved 2026-09-09T08:33:27Z
Open ↗
89
Published evidence snapshotA Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.
pubmed · T3
Published 2026-10-01 · retrieved 2026-09-10T08:34:32Z
Open ↗
90
Published evidence snapshotTirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.
pubmed · T3
Published 2026-09-08 · retrieved 2026-09-09T08:33:27Z
Open ↗
91
Published evidence snapshotTirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-11T08:35:08Z
Open ↗
92
Published evidence snapshotAnesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
pubmed · T3
Published 2026-09-09 · retrieved 2026-09-11T08:35:08Z
Open ↗
93
Published evidence snapshotComparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
pubmed · T3
Published 2026-09-10 · retrieved 2026-09-11T08:35:08Z
Open ↗
94
Published evidence snapshotIncreased Energy Expenditure through Intermittent Cold Exposure Does Not Enhance Tirzepatide Induced Weight-loss in Obese Mice.
pubmed · T3
Published 2026-09-10 · retrieved 2026-09-11T08:35:08Z
Open ↗